Two guys, a living room, and $1.8B in AI-fueled sales

In 2024, Sam Altman predicted that AI would inevitably birth a single-person billion-dollar company. It sounded like standard Silicon Valley hyperbole until a 41-year-old entrepreneur in Los Angeles actually pulled it off from his living room. And no, he didn't build an AI foundation model. He sells weight-loss pills.

His company is called Medvi, a telehealth platform selling GLP-1 medications—the popular compounds behind Ozempic and Wegovy. Matthew Gallagher built it with just $20,000 in seed money and two months of work. No formal office, no call centers, and literally two full-time employees: Gallagher and his brother.

Running an empire on off-the-shelf software

According to financial figures verified by The New York Times, Medvi pulled in $401 million in revenue during its first year in 2025. Right now, its annualized sales run rate sits at a staggering $1.8 billion, serving over 250,000 customers with a healthy 16.2% net profit margin.

Gallagher isn't a coder. Instead, he designed Medvi from day one as a hyper-automated shell where internal friction is reduced to zero. Every heavy-lifting physical component is completely outsourced: medical consultations and prescription approvals are sub-contracted through CareValidate and OpenLoop, while shipping and fulfillment are 100% third-party.

Everything else is handled by commercial AI models. Custom AI agents paired with ElevenLabs voice synthesis manage end-to-end customer support. Marketing assets rely entirely on Midjourney for visuals and Runway for promotional video generation—no photographers, no film crews, no editors. For code generation, marketing copy, and high-level strategy, Gallagher simply switches between ChatGPT, Claude, and Grok.

Aside from a handful of part-time contractors for account management and engineering tweaks, the operational core remains just the two brothers.

Why it matters

Medvi proves that the real wealth created by the generative AI wave might not go to the teams training models, but to practical operators weaponizing existing AI into legacy, high-margin consumer markets.

For solo founders and small agencies, this provides an undeniable playbook: don't reinvent the wheel. Find a red-hot market with massive existing demand, delegate physical liability and logistics to specialized third-party infrastructure, and paste AI models into every operational bottleneck that previously required junior staff.

For traditional corporations carrying thousands of salaried employees to run customer service, basic coding, and media production, cases like Medvi are a wake-up call. Competing against an agile operation with virtually zero overhead is an uphill battle.

That said, we think caution is warranted. Medvi's moat looks paper-thin. At its core, the company is an ultra-lean marketing and customer-acquisition engine surfing the massive wave of GLP-1 hype. When regulatory scrutiny tightens around telehealth prescriptions or third-party medical partners face compliance friction, two people in a living room will have a hard time defending an empire.